Description: Allergy Therapeutics Plc is a pharmaceutical company. The Company focuses on the treatment and prevention of allergy with aluminum-free products. The Company's segments are Central Europe, which includes segments, such as Germany, Australia, Switzerland and the Netherlands; Southern Europe, which includes Italy and Spain; the United Kingdom, and Rest of World. The Company provides information to healthcare professionals about the prevention, diagnosis and treatment of allergic conditions with focus on allergy vaccination, which is also known as specific immunotherapy or desensitization therapy. The Company's products include Pollinex Trees, Pollinex Grasses+Rye, Skin Prick Testing and diagnostic products. Its vaccines trade under various brand names, such as Pollinex Quattro, Polligoid and TA Graser Top. It uses specialized systems to process the Tyrosine to form a suspension microcrystalline tyrosine (MCT) that is combined with some of its subcutaneous injected therapies.
Home Page: www.allergytherapeutics.com
AGY Technical Analysis
Dominion Way
Worthing,
BN14 8SA
United Kingdom
Phone:
44 1903 844 700
Officers
Name | Title |
---|---|
Mr. Manuel Llobet | CEO & Exec. Director |
Mr. Martin Hopcroft | Interim Chief Financial Officer |
Ms. Beverly Lees | Group Operations Director |
Dr. Murray Skinner | Chief Scientific Officer |
Mr. Santiago Puig | Bus. Devel. Director |
Ms. Sue Baker | Head of HR |
Simon Piggott | Head of Clinical Science |
Alan Bullimore | Head of Communication & Market Devel. |
Mr. Russell Picket | Group Financial Controller |
Sara Goldsbrough | Company Sec. |
Exchange: LSE
Country: UK
Currency: Pence sterling (p)
GIC Sector: | Health Care |
---|---|
GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
GIC Industry: | Pharmaceuticals |
GIC Sub-Industry: | Pharmaceuticals |
Forward PE: | 0 |
---|---|
Trailing PE: | 0 |
Price-to-Book MRQ: | 2.0782 |
Price-to-Sales TTM: | 1.0849 |
IPO Date: | |
Fiscal Year End: | June |
Full Time Employees: | 600 |